Central Laboratories outperformed within the Biopharma segment, growing 11% (5% organic constant currency), while Early Development remained relatively flat during strategic restructuring.Operational efficiency is being enhanced through the 'LaunchPad' initiative, which utilizes AI and robotics to streamline laboratory operations and improve digital pathology turnaround times.The health system partnership strategy continues to expand the patient network, highlighted by a new nationwide collaboration with Ch ...